Brolucizumab

Brolucizumab is a humanized single-chain antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A). It is primarily used to treat conditions associated with abnormal blood vessel growth and leakage in the eye, such as neovascular (wet) age-related macular degeneration (AMD). By blocking VEGF-A, Brolucizumab helps reduce fluid accumulation, slow disease progression, and improve visual outcomes.

Indications

- Neovascular (wet) age-related macular degeneration (AMD) - Other ocular conditions associated with VEGF-A-mediated neovascularization (off-label, as per physician discretion)

Dosage

- Initial phase: Intravitreal injection of 6 mg every 4 weeks for the first 3 months - Maintenance phase: Every 8–12 weeks, based on disease activity and physician assessment - Dosage adjustments may be required depending on patient response and ocular health

Contra-Indications

- Hypersensitivity to Brolucizumab or any component of the formulation - Active ocular or periocular infections - Intraocular inflammation at the time of injection

Special Precautions

- Monitor patients for intraocular inflammation, retinal vasculitis, or vascular occlusion - Careful use in patients with a history of stroke, thromboembolic events, or uncontrolled hypertension - Avoid in pregnant or breastfeeding women unless clearly needed and approved by a physician - Proper sterile technique during intravitreal injection to prevent endophthalmitis

Side Effects

Common: - Conjunctival hemorrhage - Eye pain or discomfort - Floaters or blurred vision - Increased intraocular pressure Serious (rare): - Intraocular inflammation (uveitis) - Retinal vasculitis or vascular occlusion - Endophthalmitis (infection inside the eye)

Drug Interactions

- No significant systemic drug interactions reported, as Brolucizumab is administered locally in the eye - Caution with other intravitreal anti-VEGF agents; consult ophthalmologist